Your Health and Fitness Partner: Androxal & FitHub

We are also excited to expand our scope by including valuable information on Androxal, a potent medication beneficial in various medical conditions. This remarkable drug, derived from the testosterone molecule, has made its mark significantly in the field of endocrinology. Patients and medical professionals can rely on our comprehensive, unbiased, and scientifically grounded content on Androxal for gaining a robust understanding of its uses, side effects, and the latest studies related to it. We understand the necessity of accurate information when it comes to medication. Our newly launched section dedicated to Androxal aims at not only educating the readers about its nuances but also at contributing beneficially to their wellbeing. Stay tuned for insightful articles unraveling the potential of Androxal in medical science.

Sitemap | Policies | Feedback    
 About the Journal
Editorial Board
Journal Subscription
Instructions for Authors
E-mail Alerts
Forthcoming Events
Advertise with Us
Contact Us
 
Article Options
FULL TEXT
ABSTRACT
PDF
Printer Friendly Version
Search Pubmed for
Search Google Scholar for
Article Statistics
Bookmark and Share
 
Factors Affecting Non-adherence to Medications in Patients with Inflammatory Bowel Disease-Ulcerative Colitis
 
Surender Kumar, Rishabh Gupta, Hitesh Kumar Sharma, Sudhir Maharshi, Kamlesh Kumar Sharma, Vijyant Tak, Rupesh Kumar Pokharna
Department of Gastroenterology, Sawai Man Singh Medical College, Jaipur, India.


Corresponding Author
:
Dr. Rupesh Kumar Pokharna
Email: rkpokharna2@rediffmail.com


Abstract

Background / Aim: Non-adherence to treatment is an important determinant of relapses and complications in Inflammatory bowel disease-ulcerative colitis (IBD-UC). We assessed the adherence to treatment advised in IBD-UC and reasons for non-adherence in tertiary government hospital.
Methods: This cross-sectional study included patients with histologically confirmed IBD-UC admitted indoor as well as those visiting outdoors between December 2020 and August 2023. Non-adherence to treatment was assessed on the basis on questionnaire and defined as medicine intake less than 80% in last two weeks.
Results: A total of 178 participants completed the questionnaire, mean age (34.17±12.3 years), average disease duration was 3.47±2.7 years, and 56 (31.5%) patients were adherent to treatment. The adherence to oral mesalamine, salfasalazine, azathioprine, oral prednisolone, tofacitinib and topical mesalamine were 38.2%, 31.3%, 66.7%, 77.8%, 83.3% and 33.3% respectively. 78 patients were receiving treatment free-of-cost, among them 31 (39.7%) were adherent. The primary reasons for non-adherence among patients were cost and unavailability (33.1%), feeling better without medications (22.9%) and forgetfulness (12.7%). Univariate analysis revealed significant association of adherence with satisfaction (p=0.001), number of hospital visits (p=0.001) and disease awareness (p=0.014). Factors such as demographics, disease characteristics and bearing treatment-cost showed no statistically significant association. Regression analysis identified patient-satisfaction as the sole predictor of medication adherence (p = 0.001).
Conclusion: One-third of patients with UC adhered to medication regimens. Adherence was significantly associated with patient satisfaction, number of hospital visits and disease awareness while education, socioeconomic status, and disease characteristics showed no association. Free-of-cost treatment did not make a difference in adherence.